Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Clinical trial NCT02860000 · COMPLETED

Trial details

NCT number: NCT02860000
Sponsor: Mayo Clinic
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Estrogen Receptor Status HER2/Neu Negative Invasive Breast Carcinoma Postmenopausal Stage III Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer

Start date: 2017-07-06
Primary completion: 2022-01-10
Enrollment: 96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.